FDA adverse-event analysis finds distinct hearing complaints across GLP-1 agonists

The wire

1. 01Researchers analyzed FDA adverse event reports through 2026 Q1 naming exenatide (576), dulaglutide (622), semaglutide (559), liraglutide (192) or lixisenatide as primary suspect with audiovestibular terms.
2. 02Dulaglutide carried a comparative reporting odds ratio of 3.06 (95% CI 2.51-3.74) for hypoacusis, a signal clinicians may field from patients reporting hearing changes.
3. 03Authors call the findings hypothesis-generating only; they do not establish incidence or causality, and valid onset dates existed for just 19.3% of reports.

From the source

Audiovestibular adverse event reporting profiles of GLP-1 receptor agonists: A case-case pharmacovigilance study using FDA AEMS data

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026 Oct 13 · Wang X, Du D, Liu R et al.